Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Goldman Sachs Downgrades Passage Bio to Neutral, Lowers Price Target to $6

Goldman Sachs analyst Madhu Kumar downgrades Passage Bio (NASDAQ:PASG) from Buy to Neutral and lowers the price target from $29 to $6.

byBenzinga Newsdesk

January 19, 2022

1 minute read

Goldman Sachs analyst Madhu Kumar downgrades Passage Bio (NASDAQ:PASG) from Buy to Neutral and lowers the price target from $29 to $6.

News

Upstart And The National Bankers Association Partner To Provide AI Lending Technology For Minority-Owned Banks

By Benzinga Newsdesk

Today, 12:48 PM

Upstart (NASDAQ:UPST), a leading artificial intelligence (AI) lending platform, and the National Bankers Association (NBA) today announced a partnership to improve access to affordable credit for customers of

UPST

Keybanc Maintains Overweight on Phreesia, Raises Price Target to $45

By Benzinga Newsdesk

Today, 12:48 PM

Keybanc analyst Scott Schoenhaus maintains Phreesia (NYSE:PHR) with a Overweight and raises the price target from $40 to $45.

PHR

News

5 Value Stocks To Watch In The Utilities Sector

By Benzinga Insights

Today, 12:48 PM

What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

CREG